To the Editor Sodium-glucose co-transporter 2 (SGLT2) inhibitor therapy is a specific mode of anti-diabetic strategy that significantly improves cardiovascular outcomes.1 The recently published article by Joshi et al 1 has focused on beneficial effects of SGLT2 inhibitors in the setting of heart failure (HF). We fully agree that complex cellular mechanisms, beyond diuresis,1 seem to underlie pleitrophic actions of these agents. More specifically, it also seems likely that SGLT2 inhibitors might potentiate favourable effects of certain metabolic agents including cellular anti-ischaemics (and vice versa) in patients with diabetes with cardiovascular disease. Accordingly, combination of SGLT2 inhibitors with cellular anti-ischaemic regimens might have important implications in these …

中文翻译：

---

Joshi 等人关于“钠-葡萄糖协同转运蛋白 2 抑制剂治疗：心力衰竭的作用机制”的通讯

致编辑 钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂治疗是一种特定的抗糖尿病策略模式，可显着改善心血管结局。1 Joshi 等人最近发表的文章 1 重点关注了 SGLT2 抑制剂在糖尿病中的有益作用。心力衰竭（HF）的情况。我们完全同意，除了利尿作用之外，复杂的细胞机制1似乎是这些药物多效作用的基础。更具体地说，SGLT2抑制剂似乎也可能增强某些代谢药物的有利作用，包括细胞抗缺血药物（反之亦然）对患有心血管疾病的糖尿病患者。因此，SGLT2 抑制剂与细胞抗缺血方案的组合可能对这些……产生重要影响。